China Traditional Chinese Medicine (570.HK) - Short-Term Performance Pressure Is Hard to Avoid
354 Views19 Jul 2022 08:54
For poor performance of concentrated TCM granule, China TCM's net profit decreased 50%-60% in 2022H1.Future VBP will further drag down profitability, which will struggle to support valuation expansion
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (July.29)-Subsidy for VBP, Unpredictable NMPA, Ways for Internationalization31 Jul 2022
- Micro-Tech Nanjing (688029.CH) - Potential for Reversals Despite Short-Term Pressure on Performance28 Jul 2022
- China Resources Medical - Hard to Earn High Profits Due to Poor Business Model and Policy Risk25 Jul 2022
- China Healthcare Weekly (July.15)-7th VBP, Policy Correction Signs, Orthopedic Spine Consumables VBP17 Jul 2022
- China Healthcare Weekly (July.1)- TCM New Policy, Private Hospitals Survival Pressure, Sino Biopharm03 Jul 2022
- Gushengtang (2273.HK) - The Development Momentum Is Good, but There Are Also Challenges28 Jun 2022
x